Immunome Inc.

NASDAQ: IMNM · Real-Time Price · USD
10.23
0.29 (2.92%)
At close: Aug 15, 2025, 12:19 PM

Immunome Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
9.04M 14.02M n/a n/a
Cost of Revenue
n/a 728K 631K 755K
Gross Profit
9.04M 14.02M -631K -755K
Operating Income
-305.8M -109.53M -36.9M -25.2M
Interest Income
12.84M 2.72M 5K 10K
Pretax Income
-292.96M -106.81M -36.9M -24.71M
Net Income
-292.96M -106.81M -37.51M -24.71M
Selling & General & Admin
32.95M 19.66M 13.63M 11.09M
Research & Development
129.54M 23.09M 23.27M 14.11M
Other Expenses
152.34M 80.8M -631K n/a
Operating Expenses
314.84M 123.55M 36.27M 25.2M
Interest Expense
n/a n/a 5K 10K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
314.84M 123.55M 36.9M 25.2M
Income Tax Expense
n/a n/a 617K n/a
Shares Outstanding (Basic)
58.64M 19.84M 12.13M 11.54M
Shares Outstanding (Diluted)
58.64M 19.84M 12.13M 11.54M
EPS (Basic)
-5 -5.38 -3.09 -2.14
EPS (Diluted)
-5 -5.38 -3.09 -2.14
EBITDA
-151.35M -28M -36.27M -23.95M
EBIT
-153.46M -28.73M -36.9M -24.7M
Depreciation & Amortization
2.1M 728K 631K 755K